FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

VYKAT XR was approved by the FDA on March 26, 2025, for treating hyperphagia in PWS patients aged 4 and older. Common adverse reactions included hypertrichosis, edema, hyperglycemia, and rash.

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.

REDWOOD CITY, Calif. - Soleno Therapeutics, Inc. (NASDAQ:SLNO), whose stock has surged 116% over the past year and is trading near its 52-week high of $85.36, presented new data on VYKAT XR (diazoxide ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, TD ...

Investing.com - TD Cowen initiated coverage on Soleno Therapeutics Inc. (NASDAQ: SLNO) with a buy rating and a price target of $110.00 on Monday.The company, currently valued at $4.03 billion, has ...

Here’s why this is a deal you can’t afford to pass up: Access to our Detailed Report on our AI, Tariffs, and Nuclear Energy Stock with 100+% potential upside within 12 to 24 months ...

The research firm highlighted Vykat XR as the first-approved treatment for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder. TD Cowen noted that the drug "bucked the trend of ...

In April 2025, Vykat XR featured an extended-release formulation of diazoxide choline, the crystalline salt form of diazoxide. While its precise mechanism of action remains uncertain, ...